- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05267665
Envolvimento familiar no tratamento de PTSD (FIT-PTSD): um método breve e viável para melhorar resultados, retenção e envolvimento
Although effective treatments for PTSD exist, high rates of treatment dropout and sub-optimal response rates remain common. Incorporating family members in treatment represents one avenue for improving outcomes and providing Veteran-centered care, and surveys of Veterans in outpatient VA PTSD care indicate that 80% desire family involvement. The VA has invested many years and millions of dollars on the dissemination of Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE) for PTSD. A family-based intervention that complements these two first-line treatments would capitalize on existing treatment infrastructure while also potentially boosting outcomes and retention.
Preliminary testing of the proposed Brief Family Intervention (BFI) resulted in 50% less dropout from CPT/PE among Veterans whose family members received the BFI. There was also a large impact on PTSD symptoms at 16 weeks (d = 1.12) in favor of the BFI group. The goal of this study is to test the effectiveness of the BFI among a fully-powered sample. One hundred Veteran-family member dyads (n = 200) will be recruited. Veterans will be beginning a course of usual-care CPT or PE at one of two VA sites. Family members will be randomized to receive or not receive the BFI, a two-session psychoeducational and skills-based protocol. PTSD symptom severity and treatment retention will be the primary outcomes. Assessments will be conducted by independent evaluators at baseline, 6-, 12-, 18-, and 26-weeks. Veterans whose family members receive the BFI are expected to have lower dropout and a greater rate of change in their PTSD symptoms compared to Veterans whose family members do not receive the BFI. If the BFI is found to increase the effectiveness of and retention in CPT/PE, it will be a highly appealing option for incorporating families into Veterans' PTSD care.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Johanna Thompson-Hollands, PhD
- Número de telefone: (857) 364-2067
- E-mail: Johanna.Thompson-Hollands@va.gov
Estude backup de contato
- Nome: Cameron Busser, BA
- Número de telefone: (857) 364-4143
- E-mail: cameron.busser@va.gov
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02130-4817
- Recrutamento
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
-
Contato:
- Johanna Thompson-Hollands, PhD
- Número de telefone: (857) 364-2067
- E-mail: Johanna.Thompson-Hollands@va.gov
-
Investigador principal:
- Johanna Thompson-Hollands, PhD
-
Contato:
- Cameron Busser, BA
- Número de telefone: (857) 364-4143
- E-mail: cameron.busser@va.gov
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705-3875
- Recrutamento
- Durham VA Medical Center, Durham, NC
-
Contato:
- Nicole Pukay-Martin, PhD
- Número de telefone: 17-7548 919-286-0411
- E-mail: nicole.pukay-martin@va.gov
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45220
- Recrutamento
- Cincinnati VA Medical Center, Cincinnati, OH
-
Contato:
- Nicole Pukay-Martin, PhD
- Número de telefone: 3251 513-861-3100
- E-mail: nicole.pukay-martin@va.gov
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Inclusion criteria for Veterans will include:
-
a current DSM-5 diagnosis of PTSD
-
Veteran status
-
willing to have a family member involved in the study
-
has recently begun or is currently initiating individual CPT or PE (completed no more than 3 sessions of the protocol at the time of the baseline assessment)
- If taking psychotropic medication, the Veteran must be on a stable dose for at least 30 days.
Inclusion criteria for family members will include:
- age 18 or older, family member of the Veteran (significant other, parent, adult child, sibling, etc.)
- currently having frequent contact with the Veteran (three or more times per week)
Exclusion Criteria:
Exclusion criteria for Veterans will include:
- current engagement in couple/family treatment with the identified family member participant
- current severe substance use disorder (mild/moderate use disorders will not be excluded; any level of nicotine or caffeine use disorder accepted)
- current psychosis or unstable bipolar disorder diagnosis
- high suicidal risk
- significant cognitive impairment
Exclusion criteria for family members will include:
- same as listed for Veterans. Additionally
- family members will NOT be permitted to participate if they meet criteria for current PTSD
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: BFI
Family members in this arm receive the 2-session BFI intervention. |
A 2-session psychoeducational and skills-based family intervention. |
|
Sem intervenção: No BFI
Family members in this arm do not receive the BFI sessions |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Prazo: Week 26
|
Severity of PTSD symptoms. Minimum score is 0 (best possible, no symptoms) and maximum score is 80 (worst possible, highest symptoms). |
Week 26
|
|
Adequate treatment dose
Prazo: Week 26
|
Categorical evaluation of whether the participant received 8 or more on-protocol sessions of CPT or PE during their 26-week study participation period. Possible scores are 0 (meaning <8 sessions received; this is considered a poor outcome) or 1 (meaning 8 or more sessions received; this is considered a good outcome). |
Week 26
|
|
Treatment dropout
Prazo: Week 26
|
Categorical evaluation of whether the participant dropped out of treatment early. Possible scores are 0 (meaning participant did not drop out of treatment early; this is considered a good outcome) or 1 (meaning participant did drop out of treatment early; this is considered a poor outcome). |
Week 26
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Homework compliance
Prazo: Week 26
|
Compliance with assigned homework during treatment. Minimum score is 0 (worst possible), maximum score is 150 (best possible). |
Week 26
|
|
Quality of Life Inventory (QOLI)
Prazo: Week 26
|
Quality of life. Minimum score is -6 (worst possible), maximum score is 6 (best possible). |
Week 26
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Johanna Thompson-Hollands, PhD, VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- MHBP-005-21S
- 1I01CX002339-01A1 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
An anonymous dataset that meets VA standards for disclosure to the public will be made available within 1 year of publication. Prior to distributions, a privacy officer at the primary site will certify that all datasets contain no PHI. The PI will create a de-identified dataset that will include all publication variables. To remove some PHI, loss of information may occur. The PI will replace any identifiable information with study-specific numbers. Data collected on age will be replaced by the PI with age categories to ensure data is in accordance with PHI requirements for people 85 years of age and older (if applicable).
Prazo de Compartilhamento de IPD
An anonymous dataset that meets VA standards for disclosure to the public will be made available within 1 year of publication. The data will be made available until the data is destroyed according to the required timelines in the VA Record Control Schedule.
Critérios de acesso de compartilhamento IPD
Individual requesting access to the data will be required to complete an adequate Data Use Agreement.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .